Pittsburgh, PA, United States of America

Peter Wipf

USPTO Granted Patents = 83 (Patent Applications = 23)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 13)

Average Co-Inventor Count = 3.2

ph-index = 9

Forward Citations = 256(Granted Patents)

Forward Citations (Not Self Cited) = 155(Oct 12, 2025)

Inventors with similar research interests:

Location History:

Pittsburg, PA (US) (2012)
Pittsburgh, PA (US) (1997 - 2023)

Company Filing History:

82 out of 1,860

University of Pittsburgh

patents

4 out of 972

University of Arizona

patents

3 out of 995

University of Virginia

patents

4. 3 out of 3,435

National Institutes of Health, a Component of the US Dept. of Health & Human Services

patents

5. 2 out of 6

Prolx Pharmaceuticals Corporation

patents

6. 2 out of 173

Musc Foundation for Research Development

patents

7. 2 out of 3,682

The Johns Hopkins University

patents

8. 2 out of 15,458

University of California

patents

9. 2 out of 261

Arizona Board of Regents, a Body Corporate

The Brigham and Women's Hospital, Inc.

patents

12. 1 out of 1

Proix Pharmaceutical Corp.

patent

where one patent can have more than one assignee

Years Active: 1997-2025

Loading Chart...

83 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12486231 - Targeted nitroxide compounds and their use in treating ferroptosis-related diseases (2025-12-02),

2. 12227515 - In-flow photooxygenation of aminothienopyridinones generates novel PTP4A3 phosphatase inhibitors (2025-02-18),

3. 12202839 - In-flow photooxygenation of aminothienopyridinones generates PTP4A3 phosphatase inhibitors (2025-01-21),

4. 12202811 - Compounds for treating prostate cancer (2025-01-21),

5. 12128038 - Method of treatment of organic acidemias and other mitochondria defects or deficiencies (2024-10-29),

6. 11773075 - Modulators of p97 AAA ATPase activity (2023-10-03),

7. 11766433 - Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer (2023-09-26),

8. 11759524 - Mitochondrially targeted PARP inhibitor, and uses thereof (2023-09-19),

9. 11718600 - 1,2,3-triazole inhibitors of P97 AAA ATPase activity (2023-08-08),

10. 11413299 - Compositions and methods for treatment of inflammatory disorders (2022-08-16),

11. 11358930 - Selective potassium channel agonists (2022-06-14),

12. 11247985 - Phenyl indole allosteric inhibitors of P97 ATPase (2022-02-15),

13. 11214560 - Modulators of P97 AAA ATPase activity (2022-01-04),

14. 11111253 - 6-aryl-7-substituted-3-(1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines as inhibitors of the STAT3 pathway with anti-proliferative activity (2021-09-07),

15. 11090389 - Mitochondrially targeted PARP inhibitor, and uses thereof (2021-08-17),

Title: The Innovative Journey of Peter Wipf

Introduction: Peter Wipf, a distinguished inventor based in Pittsburgh, PA, has made significant contributions to the field of innovation with his groundbreaking work in various patents and inventions.

Latest Patents: Peter Wipf holds several patents in the areas of pharmaceuticals, organic chemistry, and materials science, showcasing his versatility and expertise in multiple domains of innovation.

Career Highlights: Throughout his illustrious career, Peter Wipf has been recognized for his pioneering research and inventive spirit, leading to the development of cutting-edge technologies that have revolutionized their respective industries.

Collaborations: Peter Wipf has collaborated with top research institutions, universities, and companies worldwide, fostering a culture of innovation and knowledge exchange that has propelled his inventions to new heights of success.

Conclusion: Peter Wipf's unwavering dedication to innovation, coupled with his exceptional talent and collaborative efforts, continues to inspire the next generation of inventors and researchers to push the boundaries of what is possible in the world of patents and inventions.

This text is generated by artificial intelligence and may not be accurate.